Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain

NCT04978454 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Influenza RG-A/Texas/71/2017 (H3N2) Challenge
OTHER: Placebo

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)